New drug cocktail shows promise for tough lymphomas

NCT ID NCT01657331

Completed Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs worked together. The trial has been completed, and results may help doctors treat these hard-to-manage lymphomas.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brentuximab vedotin and bendamustine
What this could lead to: If successful, this combination could offer a new treatment option for patients whose lymphoma has returned or not responded to prior therapy.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC LARGE CELL LYMPHOMA HODGKIN LYMPHOMA

Contacts and locations

Locations

British Columbia Cancer Agency

Vancouver, British Columbia, V5z 4E6, Canada
Center for Lymphoid Malignancies at CUMC

New York, New York, 10010, United States
Princess Margaret Hospital

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.